Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC ORY-1001 1431326-61-2 10mM (in 1mL DMSO)
Supplier: Apexbio Technology LLC B58825.1
ORY-1001 is a selective inhibitor targeting the lysine-specific histone demethylase KDM1A (also known as LSD1) an FAD-dependent amine oxidase enzyme responsible for the removal of histone methylation marks particularly dimethylation of histone H3 lysine 4 (H3K4me2) By inhibiting KDM1A ORY-1001 promotes accumulation of H3K4me2 at gene targets and induces cellular differentiation in acute myeloid leukemia (AML) cell models In vitro assays demonstrated dose- and time-dependent increases in H3K4me2 and expression of differentiation markers in treated AML cells ORY-1001 exhibited oral bioavailability in animal xenograft models reducing tumor growth at low daily doses This molecule serves as a valuable research tool in epigenetics oncology pharmacology and studies regarding AML differentiation pathways with ongoing evaluation in early-phase clinical trials
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?